ExonHit Therapeutics Inc. and bioMerieux, Inc. Decide Not to Pursue Colon Cancer Program

ExonHit Therapeutics Inc. and bioMerieux, Inc. Decide Not to Pursue Colon Cancer Program
PARIS--(BUSINESS WIRE)-- ExonHit Therapeutics and bioMérieux have decided not to pursue their collaboration in colon cancer, following a recent review of data by their scientific committee. Both companies continue to collaborate in the field of prostate cancer.

"ExonHit's technology was able to produce a robust and reproducible test however, the final results from the colon cancer program did not reach the level of performance we were aiming to achieve. Therefore, we have decided together with bioMérieux to focus our efforts on the prostate cancer program," commented Loïc Maurel, M.D., President of the Management Board of ExonHit Therapeutics.

"Biomarker discovery is a strategic focus of innovation research for bioMerieux, but is a challenging scientific, medical and business endeavor. We made the decision to stop this Colon cancer screening Research program with ExonHit after reviewing the results of the clinical data. Our teams have learned a lot about this important disease", said Stéphane Bancel, Chief Executive Officer of bioMérieux. "We look forward to continuing our collaboration together in the area of prostate cancer."

ExonHit and bioMérieux collaboration is dedicated to the discovery of biomarkers for the detection of certain cancers.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast-emerging healthcare player active in both therapeutics and diagnostics. The company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The company is listed on Alternext of NYSE Euronext Paris. For more information, please visit http://www.exonhit.com.


This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Lastly, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.


ExonHit Therapeutics Corinne Hoff +33 1 58 05 47 04 [email protected] or Alize RP Caroline Carmagnol + 33 6 64 18 99 59 [email protected]